Former FDA Hematologic Malignancies Leader Nicholas Richardson Joins Precision for Medicine as VP Clinical Development
Key Insights
Nicholas Richardson, DO, MPH, former Deputy Director for the Division of Hematologic Malignancies (search) 2 at the FDA, has joined Precision for Medicine (search) as Vice President, Clinical Development.
Dr. Richardson brings nine years of FDA experience and deep expertise in CAR-T cell therapies (search), bispecifics (search), and T-cell engagers (search) for treating lymphoma (search), chronic lymphocytic leukemia (search), and multiple myeloma (search).
His regulatory expertise in developing novel endpoints such as minimal residual disease (search) in blood cancers will help accelerate drug development pathways for life science companies.
Precision for Medicine (search), a global leader in biomarker-driven clinical research and development, announced that Nicholas Richardson, DO, MPH, has joined the company as Vice President, Clinical Development. Dr. Richardson, an expert in pediatric hematology and oncology, was previously Deputy Director for the Division of Hematologic Malignancies (search) 2 at the U.S. Food and Drug Administration (FDA), which oversees the development of therapeutics for patients with lymphoma (search), chronic lymphocytic leukemia (search) (CLL) and multiple myeloma (search).
Regulatory Expertise in Blood Cancer Therapeutics
Working over nine years at the FDA, Dr. Richardson developed profound understanding of regulatory strategy, particularly in the development of CAR-T cell therapies (search), bispecifics (search) and T-cell engagers (search). His expertise will guide clients through the evolving regulatory landscape for hematologic malignancies (search) as they develop drugs, biologics, and cell and gene therapies.
Dr. Richardson spearheaded initiatives to develop novel endpoints in blood cancer, such as minimal residual disease (search) (MRD) in lymphoma (search) and CLL, accelerating drug development. These innovative approaches to measuring treatment efficacy have become increasingly important in the regulatory approval process for blood cancer therapeutics.
Strategic Leadership Addition
"I am thrilled to welcome Dr. Nicholas Richardson, a distinguished colleague from the FDA's Oncology Center of Excellence, to Precision for Medicine (search)," said Harpreet Singh, MD, Precision for Medicine's Chief Medical Officer, who formerly served as an FDA Oncology Division Director. "Dr. Richardson is a proven leader in innovative trial design, biomarkers and cutting-edge cell therapies, and his unique skill set will directly accelerate our approach to blood cancer treatments. Furthermore, his deep, long-standing relationships within the CLL, lymphoma (search) and myeloma communities will deliver immense strategic value to our clients."
Dr. Richardson's expertise in hematologic malignancies (search) and cell and gene therapies complements Dr. Singh's expertise in solid tumor therapies, creating comprehensive development leadership for oncology treatments across the company's service offerings.
Mission-Driven Approach
"My career has been dedicated to transforming the blood cancer treatment landscape and ensuring safe, effective therapies reach patients. Joining Precision for Medicine (search) represents a pivotal next step in that mission," said Dr. Richardson. "I am eager to leverage the collective expertise here and across the industry to optimize drug development pathways, ultimately empowering manufacturers to bring critical, life-saving treatments to patients with speed and efficiency."
In his new role, Dr. Richardson will be responsible for partnering with life science companies on the clinical development of their therapeutic programs, bringing his regulatory insights and clinical development experience to bear on advancing treatments for patients with blood cancers.
About Precision for Medicine
Precision for Medicine (search) positions itself as the first biomarker-driven clinical research and development services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. The company applies a transformational approach to clinical research that integrates clinical trial design and execution with deep scientific knowledge, laboratory expertise and advanced data intelligence. Precision for Medicine is part of Precision Medicine Group (search), with 3,600 people in 40 locations globally across North America, Europe and Asia-Pacific.